Name: Bimatoprost
Brand: Selleck Chemicals
SKU: S1407
Availability: InStock
Rating: 5 (2 reviews)

Jump to

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	CXCR Hedgehog/Smoothened PKA Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas
Other Prostaglandin Receptor Inhibitors	PF-04418948 E7046 (ER-886406) TG4-155 RO1138452 Ethamsylate Grapiprant (CJ-023,423) Timapiprant Sodium Seratrodast(AA-2414) BI-671800 Setipiprant (ACT-129968)

Solubility

In vitro
Batch:

DMSO : 83 mg/mL (199.72 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 83 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.150mg/ml (9.99mM)	Taking the 1 mL working solution as an example, add 50 μL of 83 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.510mg/ml (1.23mM)	Taking the 1 mL working solution as an example, add 50 μL of 10.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	415.57	Formula	C₂₅H₃₇NO₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	155206-00-1	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	AGN 192024			SMILES	CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro	Bimatoprost mildly stimulates the rate of aqueous humor flow during the day (13%) and at night (14%), its ocular hypotensive action is due primarily to a 26% reduction in the tonographic resistance to outflow. This compound enhances the pressure-sensitive outflow pathway. It displaces [³H]prostaglandin F(2alpha) from FP receptors with K(i) of 6.31 μM. This chemical rapidly mobilizes intracellular Ca(2+) via cloned human FP receptors expressed in human embryonic kidney cells and via native FP receptors in 3T3 mouse fibroblasts with EC(50) of 2.94 μM and 2.2 μM. It up-regulates Cyr61 mRNA expression in the cat iris. This compound-induced up-regulation of Cyr61 mRNA expression is not because of the activation of the prostaglandin FP receptor but a different receptor. It consistently evokes responses in different cells within the same tissue preparation, whereas prostaglandin F(2 alpha) and 17-phenyl prostaglandin F(2 alpha) elicites signaling responses in the same cells. This chemical selectively stimulates intracellular calcium signaling in different cat iris sphincter cells.
In vivo	Bimatoprost is the ethyl amide derivative of 17-phenyl trinor PGF2α, a potent prostaglandin FP receptor agonist. This compound elicits an immediate, robust spike in [Ca²⁺] that rapidly decayes back to baseline levels. It possess direct agonist activities at the rat, mouse, and human FP prostanoid receptor.
References	[1] https://pubmed.ncbi.nlm.nih.gov/11434937/ [2] https://pubmed.ncbi.nlm.nih.gov/11740958/ [3] https://pubmed.ncbi.nlm.nih.gov/12724323/ [4] https://pubmed.ncbi.nlm.nih.gov/15652534/ [5] https://pubmed.ncbi.nlm.nih.gov/12490597/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03708627	RECRUITING	Graves Ophthalmopathy	Johns Hopkins University	2017-11-01	EARLY_PHASE1
NCT07218796	RECRUITING	Cataract; Glaucoma; Ocular Hypertension	SpyGlass Pharma, Inc.	2025-10-28	PHASE3
NCT07218783	RECRUITING	Cataract; Glaucoma; Ocular Hypertension	SpyGlass Pharma, Inc.	2025-10-15	PHASE3
NCT07217678	RECRUITING	Glaucoma; Open-Angle Glaucoma; Ocular Hypertension; Glaucoma Suspect	University of Miami	2026-02-09	PHASE4
NCT07661329	RECRUITING	Primary Open Angle Glaucoma (POAG); Ocular Hypertension (OH)	YS Life Science Co., Ltd.	2026-06-02	PHASE3
NCT07641296	NOT_YET_RECRUITING	Glaucoma; Ocular Hypertension	SpyGlass Pharma, Inc.	2026-07-31	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Bimatoprost Prostaglandin Receptor agonist

Chemical Structure

Molecular Weight: 415.57